The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis

被引:325
作者
Schmitt, J [1 ]
Wozel, G [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Dermatol, DE-01307 Dresden, Germany
关键词
plaque-type psoriasis; Psoriasis Area and Severity Index; dermatology life quality index;
D O I
10.1159/000083509
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index ( PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular. Objective: This article summarizes the most important objective and subjective measurements of severity in psoriasis. For every dermatologist it is critically important to distinguish between severe psoriasis and psoriasis that severely affects QOL. Even if the PASI also has disadvantages, it is the most adequate instrument available to evaluate severity in plaque-type psoriasis. Result: We provide reasons why PASI > 12 defines severe, PASI 7-12 moderate and PASI < 7 mild chronic plaque-type psoriasis. Copyright (c) 2005 S. Karger AG, Basel.
引用
收藏
页码:194 / 199
页数:6
相关论文
共 32 条
[1]  
Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185
[2]   Genetic aspects of psoriasis [J].
Barker, JNWN .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) :321-325
[3]   Efficacy and safety of etanercept in patients with psoriasis: Results of a global phase III study [J].
Elewski, BE ;
Boh, E ;
Papp, K ;
Zitnik, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) :P159-P159
[4]  
Feldman S R, 2004, J Dermatolog Treat, V15, P27, DOI 10.1080/09546630310019382
[5]   The economic impact of psoriasis increases with psoriasis severity [J].
Feldman, SR ;
Fleischer, AB ;
Reboussin, DM ;
Rapp, SR ;
Bradham, DD ;
Exum, ML ;
Clark, AR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (04) :564-569
[6]   The self-administered psoriasis area and severity index is valid and reliable [J].
Feldman, SR ;
Fleischer, AB ;
Reboussin, DM ;
Rapp, SR ;
Exum, ML ;
Clark, AR ;
Nurre, L .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (01) :183-186
[7]   VALIDATION OF SICKNESS IMPACT PROFILE AND PSORIASIS DISABILITY INDEX IN PSORIASIS [J].
FINLAY, AY ;
KHAN, GK ;
LUSCOMBE, DK ;
SALEK, MS .
BRITISH JOURNAL OF DERMATOLOGY, 1990, 123 (06) :751-756
[8]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[9]   Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis [J].
Finlay, AY ;
Salek, MS ;
Haney, J .
DERMATOLOGY, 2003, 206 (04) :307-315
[10]   PSORIASIS - AN INDEX OF DISABILITY [J].
FINLAY, AY ;
KELLY, SE .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1987, 12 (01) :8-11